# Takeda's experimental drug TAK-881 is on track for FDA review later this year.

*business · news · 2026-05-04 · MassLive*

## Key points

- Takeda's TAK-881 drug cleared a key clinical trial for Primary Immunodeficiency Disease treatment.
- TAK-881 provides the same immune protection as HYQVIA with half the infusion volume required.
- The new drug also significantly reduces administration time compared to current PID therapies.
- TAK-881 was successfully tested in both adults and children as young as 2 years old.
- Takeda aims to seek regulatory approval for TAK-881 in the US, EU, and Japan by fiscal year 2026.

**Companies:** Takeda
**Countries:** United States, Japan

[Read the full story on MassLive](https://www.masslive.com/news/2026/05/a-cambridge-pharma-giant-just-cleared-a-key-hurdle-in-treating-rare-immune-disease.html)

---

Canonical: https://newsio.io/n/d28653d2-8491-4f94-8eba-d85f5c9a59dc/takedas-experimental-drug-tak-881-is-on-track-for-fda-review-later-this-year-the
Summarized by Newsio from MassLive. https://newsio.io/how-it-works